Atenolol

Tenoretic, Tenormin (atenolol) is a small molecule pharmaceutical. Atenolol was first approved as Tenormin on 1982-01-01. It is used to treat angina pectoris, atrial fibrillation, atrial flutter, heart failure, and hypertension amongst others in the USA. The pharmaceutical is active against beta-1 adrenergic receptor. In addition, it is known to target beta-2 adrenergic receptor.

Download report

Favorite

Searched

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
cardiovascular diseases	D002318
signs and symptoms pathological conditions	D013568

Trade Name

FDA

EMA

Tenormin (generic drugs available since 1988-07-15)

Combinations

Tenoretic (generic drugs available since 1988-07-15)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Atenolol

Tradename	Company	Number	Date	Products
TENORMIN	Almatica Pharma	N-018240 RX	1982-01-01	3 products, RLD, RS

Show 1 discontinued

Atenolol

Chlorthalidone

Tradename	Company	Number	Date	Products
TENORETIC 100	Almatica Pharma	N-018760 RX	1984-06-08	1 products, RLD, RS
TENORETIC 50	Almatica Pharma	N-018760 RX	1984-06-08	1 products, RLD

Labels

FDA

EMA

Brand Name	Status	Last Update
atenolol	ANDA	2023-06-14
tenoretic	New Drug Application	2021-01-31
tenormin	New Drug Application	2021-06-30

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
angina pectoris	EFO_0003913	D000787	I20
atrial fibrillation	EFO_0000275	D001281	I48.0
atrial flutter	EFO_0003911	D001282	—
heart failure	EFO_0003144	D006333	I50
hypertension	EFO_0000537	D006973	I10
myocardial infarction	EFO_0000612	D009203	I21
supraventricular tachycardia	HP_0004755	D013617	I47.1
ventricular fibrillation	EFO_0004287	D014693	I49.01
ventricular tachycardia	—	D017180	I47.2

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

C: Cardiovascular system drugs

— C07: Beta-adrenergic blocking agents

— C07A: Beta blocking agents

— C07AB: Beta blocking agents, selective

— C07AB03: Atenolol

— C07AB11: S-atenolol

— C07B: Beta blocking agents and thiazides

— C07BB: Beta blocking agents, selective, and thiazides

— C07BB03: Atenolol and thiazides

— C07C: Beta blocking agents and other diuretics

— C07CB: Beta blocking agents, selective, and other diuretics

— C07CB03: Atenolol and other diuretics

— C07CB53: Atenolol and other diuretics, combinations

— C07D: Beta blocking agents, thiazides and other diuretics

— C07DB: Beta blocking agents, selective, thiazides and other diuretics

— C07DB01: Atenolol, thiazides and other diuretics

— C07F: Beta blocking agents, other combinations

— C07FB: Beta blocking agents and calcium channel blockers

— C07FB03: Atenolol and nifedipine

HCPCS

No data

Clinical

Clinical Trials

263 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hypertension	D006973	EFO_0000537	I10	5	6	9	20	3	40
Gout	D006073	EFO_0004274	M10	2	11	12	7	4	36
Hyperuricemia	D033461			1	7	4	4	4	20
Healthy volunteers/patients	—			8	—	1	1	3	13
Cardiovascular diseases	D002318	EFO_0000319	I98	4	1	5	1	1	11
Chronic renal insufficiency	D051436		N18	3	3	—	1	2	9
Heart failure	D006333	EFO_0003144	I50	1	5	1	3	—	8
Marfan syndrome	D008382	Orphanet_558	Q87.4	—	2	4	1	—	7
Left ventricular hypertrophy	D017379	EFO_0003896		—	—	3	3	—	6
Blood pressure	D001794	EFO_0004325		1	—	1	3	—	5

Show 35 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Precursor cell lymphoblastic leukemia-lymphoma	D054198		C91.0	2	4	2	—	1	8
Heart diseases	D006331	EFO_0003777	I51.9	1	1	5	—	—	6
Non-hodgkin lymphoma	D008228		C85.9	—	2	2	—	1	5
Obesity	D009765	EFO_0001073	E66.9	—	1	2	—	—	3
Neoplasms	D009369		C80	—	1	1	—	1	3
Prehypertension	D058246			—	2	1	—	—	2
Coronary disease	D003327			—	—	1	—	1	2
Hiv infections	D015658	EFO_0000764	B20	—	—	1	—	1	2
Tumor lysis syndrome	D015275		E88.3	—	—	2	—	—	2
Liver cirrhosis	D008103	EFO_0001422	K74.0	—	2	2	—	—	2

Show 21 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Leukemia	D007938		C95	2	6	—	—	—	8
Myelodysplastic syndromes	D009190		D46	2	3	—	—	1	6
Lymphoma	D008223		C85.9	2	3	—	—	—	5
Multiple myeloma	D009101		C90.0	1	3	—	—	—	4
Myeloid leukemia acute	D015470		C92.0	—	3	—	—	1	4
Obstructive sleep apnea	D020181	EFO_0003918	G47.33	—	1	—	—	2	3
Plasma cell neoplasms	D054219			2	1	—	—	—	3
B-cell chronic lymphocytic leukemia	D015451		C91.1	—	2	—	—	—	2
Burkitt lymphoma	D002051		C83.7	—	2	—	—	—	2
Dilated cardiomyopathy	D002311	EFO_0000407	I42.0	1	1	—	—	1	2

Show 24 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Heart disease risk factors	D000082742			3	—	—	—	—	3
Vasoconstriction	D014661			2	—	—	—	—	2
Pre-eclampsia	D011225	EFO_0000668	O14	2	—	—	—	—	2
Myeloproliferative disorders	D009196		D47.1	1	—	—	—	—	1
Graft vs host disease	D006086		D89.81	1	—	—	—	—	1
Vasodilation	D014664			1	—	—	—	—	1
Tuberculosis	D014376	EFO_0000774	A15-A19	1	—	—	—	—	1
Inflammatory bowel diseases	D015212	EFO_0003767		1	—	—	—	—	1
Morbid obesity	D009767	EFO_0001074		1	—	—	—	—	1
Osteoporosis	D010024	EFO_0003882	M81.0	1	—	—	—	—	1

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Atrial fibrillation	D001281	EFO_0000275	I48.0	—	—	—	—	2	2
Cutaneous leishmaniasis	D016773		B55.1	—	—	—	—	2	2
Aneurysm	D000783	HP_0002617	I72.9	—	—	—	—	1	1
Cachexia	D002100	HP_0004326	R64	—	—	—	—	1	1
Prediabetic state	D011236	EFO_1001121	R73.03	—	—	—	—	1	1
Exercise test	D005080	EFO_0004328		—	—	—	—	1	1
Orthognathic surgery	D057909			—	—	—	—	1	1
Endoscopic retrograde cholangiopancreatography	D002760			—	—	—	—	1	1
Iga glomerulonephritis	D005922	EFO_0004194		—	—	—	—	1	1
Fetal growth retardation	D005317	EFO_0000495		—	—	—	—	1	1

Show 6 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	ATENOLOL
INN	atenolol
Description	Atenolol is an ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent. It has a role as a beta-adrenergic antagonist, an anti-arrhythmia drug, an antihypertensive agent, a sympatholytic agent, a xenobiotic and an environmental contaminant. It is a member of ethanolamines, a monocarboxylic acid amide and a propanolamine.
Classification	Small molecule
Drug class	beta-blockers (propranolol type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	CC(C)NCC(O)COc1ccc(CC(N)=O)cc1

Identifiers

PDB	2OTF
CAS-ID	29122-68-7
RxCUI	1202
ChEMBL ID	CHEMBL24
ChEBI ID	2904
PubChem CID	2249
DrugBank	DB00335
UNII ID	50VV3VW0TI (ChemIDplus, GSRS)

Target

Agency Approved

ADRB1

Organism

Homo sapiens

Gene name

ADRB1

Gene synonyms

ADRB1R, B1AR

NCBI Gene ID

153

Protein name

beta-1 adrenergic receptor

Protein synonyms

adrenergic, beta-1-, receptor, Beta-1 adrenoceptor, Beta-1 adrenoreceptor

Uniprot ID

P08588

Mouse ortholog

Adrb1 (11554)

beta-1 adrenergic receptor (P34971)

Alternate

ADRB2

Organism

Homo sapiens

Gene name

ADRB2

Gene synonyms

ADRB2R, B2AR

NCBI Gene ID

154

Protein name

beta-2 adrenergic receptor

Protein synonyms

adrenergic, beta-2-, receptor, surface, adrenoceptor beta 2 surface, Beta-2 adrenoceptor, Beta-2 adrenoreceptor, catecholamine receptor

Uniprot ID

Q9UMZ5

Mouse ortholog

Adrb2 (11555)

beta-2 adrenergic receptor (Q8BH38)

Variants

Clinical Variant

No data

Financial

No data

Trends

PubMed Central

Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data

Additional graphs summarizing 15,813 documents

View more details

Safety

Black-box Warning

No Black-box warning

Adverse Events

Top Adverse Reactions

Mock data
Subscribe for the real data

968 adverse events reported

View more details

Real-time Data on

Companies, Drugs, and Diseases

PharmaKB

MATERIALS

COMPANY